Lemaitre Vascular (LMAT) 17.89 $LMAT Cerus (CERS) in

New Post Public Reply Private Reply Replies (0) Message Board

Aug 1, 2016 at 9:08 PM

Lemaitre Vascular (LMAT) 17.89 $LMAT

Cerus (CERS) in Focus: Stock Moves 6% Higher in Session
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 7:05AM CDT
Cerus Corporation (CERS) was a big mover last session, as the company saw its shares rise a little over 6% on the day.
CERS: 7.31 (-0.08), LMAT: 17.89 (+0.69)

LeMaitre Q2 2016 Record Sales $22.4mm (+13%), Record Op. Income $3.8mm (+35%)
GlobeNewswire - Wed Jul 27, 3:08PM CDT
LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of vascular devices, today reported Q2 2016 results, provided increased guidance, announced a $0.045/share dividend and authorized a $5.0mm share repurchase program.
LMAT: 17.89 (+0.69)

Genomic Health: Can the Liquid Biopsy Test Boost Margins?
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 7:50AM CDT
Genomic Health (GHDX) recently launched a next-generation sequencing blood-based mutational panel -- Oncotype SEQ Liquid Select.
BSX: 24.43 (+0.15), BAX: 48.50 (+0.48), LMAT: 17.89 (+0.69), GHDX: 30.34 (+1.31)

FDA Okays Trial for Medtronic's MRI-Guided Epilepsy Device
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 6:31AM CDT
With surgical procedures gaining ground in the treatment of drug-resistant epilepsy, the FDA go-ahead will expand Medtronic's (MDT) footprint in the billion-dollar neurosurgical market.
ICUI: 117.07 (+0.31), MDT: 88.06 (+0.43), BAX: 48.50 (+0.48), LMAT: 17.89 (+0.69)

Hologic: FDA Okays Procleix Zika Virus Test under IND Study
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 7:51AM CDT
Hologic's (HOLX) Procleix Zika Virus Test was approved under FDA???s Investigational New Drug (IND) study protocol to detect the presence of Zika virus in donated blood.
ICUI: 117.07 (+0.31), BAX: 48.50 (+0.48), LMAT: 17.89 (+0.69), HOLX: 38.98 (+0.49)

Walgreen Boots Hopeful on Rite Aid Buyout amid Margin Woes
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 7:26AM CDT
On Jun 22, 2016, we issued an updated research report on Walgreens Boots Alliance, Inc. (WBA).
WBA: 79.27 (+0.02), LMAT: 17.89 (+0.69), STJ: 83.73 (+0.69), NUVA: 63.29 (+1.09)

Qiagen's Q1 Results Hit by Currency, Competition Rife
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:32AM CDT
Qiagen (QGEN) is facing increasing competition from firms that provide pre-analytical solutions and other products.
BSX: 24.43 (+0.15), BAX: 48.50 (+0.48), LMAT: 17.89 (+0.69), QGEN: 26.80 (unch)

Hill-Rom Introduces VisiVest, First Connected Airways System
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 8:19AM CDT
Hill-Rom Holdings, Inc. (HRC) recently launched VisiVest System, the world's first wirelessly connected airway clearance system.
ICUI: 117.07 (+0.31), LMAT: 17.89 (+0.69), NUVA: 63.29 (+1.09), HRC: 54.02 (+0.59)

Hologic's Zika Virus Test Gets FDA Nod for Emergency Use
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 7:58AM CDT
Hologic (HOLX) will run the Aptima Zika virus test on its market leading Panther platform, which substantially reduces hands-on time for laboratories and the potential for manual errors.
ICUI: 117.07 (+0.31), BAX: 48.50 (+0.48), LMAT: 17.89 (+0.69), HOLX: 38.98 (+0.49)

AmSurg, Envision Healthcare Set to Merge by 2016-End
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 8:47AM CDT
Envision shareholders will own 53% of the combined entity while AmSurg (AMSG) shareholders will have 47%.
AMSG: 72.23 (-2.78), EVHC: 23.59 (-1.00), BAX: 48.50 (+0.48), LMAT: 17.89 (+0.69)

Genomic Health Brings Liquid Biopsy Test for Stage IV Cancer
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 7:13AM CDT
Genomic's (GHDX) Oncotype SEQ facilitates personalized treatment of patients suffering from stage four solid tumor cancer.
BAX: 48.50 (+0.48), LMAT: 17.89 (+0.69), ILMN: 170.65 (+4.30), GHDX: 30.34 (+1.31)

Qiagen???s QIAsure Test to Determine Cervical Cancer Risks
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 7:33AM CDT
Qiagen's (QGEN) QIAsure accurately stratifies cervical cancer risk, which offers highly sensitive and specific results for patients and clinicians.
BAX: 48.50 (+0.48), LMAT: 17.89 (+0.69), QGEN: 26.80 (unch), NUVA: 63.29 (+1.09)

Boston Scientific: NICE Backs GreenLight XPS for BPH Cure
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 7:01AM CDT
As per NICE's estimates, broad adoption of Boston Scientific's (BSX) GreenLight therapy over TURP can lead to savings of up to ??3.2 million annually for the National Health Service (NHS).
BSX: 24.43 (+0.15), BAX: 48.50 (+0.48), LMAT: 17.89 (+0.69), NUVA: 63.29 (+1.09)

Bruker Well Poised on Product Innovation amid Currency Woes
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 6:23AM CDT
On Jun 14, we issued an updated research report on Billerica, MA-based Bruker Corporation (BRKR).
ICUI: 117.07 (+0.31), LMAT: 17.89 (+0.69), BRKR: 24.81 (-0.11), NUVA: 63.29 (+1.09)

Boston Scientific: Restructuring Plan, Global Growth Impress
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 6:14AM CDT
On Jun 13, 2016, we issued an updated research report on Boston Scientific Corporation (BSX).
BSX: 24.43 (+0.15), ICUI: 117.07 (+0.31), BAX: 48.50 (+0.48), LMAT: 17.89 (+0.69)

PetMed Remains Strong on New Order & Reorder Sales Gain
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 10:15AM CDT
On Jun 13, 2016, we issued an updated research report on PetMed Express (PETS).
ICUI: 117.07 (+0.31), PETS: 20.81 (+0.08), LMAT: 17.89 (+0.69), NUVA: 63.29 (+1.09)

Haemonetics: Q4 Hit by Issues in Russia, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:51AM CDT
Haemonetics (HAE) posted a dismal fourth-quarter fiscal 2016 with both EPS and revenues failing to meet the Zacks Consensus Estimate.
BSX: 24.43 (+0.15), HAE: 33.52 (+3.20), BAX: 48.50 (+0.48), LMAT: 17.89 (+0.69)

Hill-Rom: Welch-Allyn Buyout Drives Q2, Forex Woes Stay
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 9:20AM CDT
Hill-Rom (HRC) posted a mixed second quarter of fiscal 2016 with the bottom line surpassing the Zacks Consensus Estimate and the top line missing the same.
BSX: 24.43 (+0.15), BAX: 48.50 (+0.48), LMAT: 17.89 (+0.69), HRC: 54.02 (+0.59)

Hologic: Q2 Strong on Segmental Expansion, Competition Rife
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:43AM CDT
Hologic (HOLX) ended second-quarter fiscal 2016 on a promising note, squarely beating the Zacks Consensus Estimate.
BSX: 24.43 (+0.15), BAX: 48.50 (+0.48), LMAT: 17.89 (+0.69), HOLX: 38.98 (+0.49)

Mead Johnson: Strong Q1 on Overseas Growth & Strategies
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 6:40AM CDT
Mead Johnson (MJN) embarked on a promising journey this year, posting square beats in the first quarter.
BSX: 24.43 (+0.15), MJN: 87.72 (-1.48), BAX: 48.50 (+0.48), LMAT: 17.89 (+0.69)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Endurance Energy's Modular Tech Revs Up Southeast Asia

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

Leo Cancer Care's Upright Radiotherapy Milestone

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

IASO's FUCASO Shows Robust Results in 2026 Study

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

China Southern Airlines Marks 70th Anniversary in NYC

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Fuse Oncology Showcases New iRT Workflow at ASTRO

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

AST SpaceMobile Faces Class Action Over Misstatements

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

Timur Turlov Leads FIDE with Chess and Digital Focus

An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...

Cut Winter Heating Costs with Townsend's Rebate Help

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Quay Shines in 2026 Prescription Sunglasses Lineup

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...